Literature DB >> 10767130

Outpatient Therapy of Deep Vein Thrombosis.

.   

Abstract

The initial treatment of acute venous thrombosis using low-molecular-weight heparin (LMWH) in the outpatient setting has been shown to be feasible, effective, and safe for selected patients when compared with in-hospital treatment using continuous intravenous heparin. There will always be a significant population of patients, however, who require in-hospital treatment with either LMWH or unfractionated heparin. It is clear that substantial cost savings can be achieved with the out-of-hospital treatment of venous thrombosis, but several logistic problems require solutions before these savings can be realized. Numerous strategies, including the development of anticoagulation management clinics, are under review, especially for the management of arterial or venous thrombosis with LMWH. It is likely that the outpatient management of venous thrombosis will vary, depending on the referral base of the institution involved.

Entities:  

Year:  1998        PMID: 10767130     DOI: 10.1023/a:1013232803747

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  43 in total

1.  Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin.

Authors:  D Green; R D Hull; R Brant; G F Pineo
Journal:  Lancet       Date:  1992-06-13       Impact factor: 79.321

Review 2.  Venous thromboembolism.

Authors:  K M Moser
Journal:  Am Rev Respir Dis       Date:  1990-01

3.  Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.

Authors:  R D Hull; G E Raskob; J Hirsh; R M Jay; J R Leclerc; W H Geerts; D Rosenbloom; D L Sackett; C Anderson; L Harrison
Journal:  N Engl J Med       Date:  1986-10-30       Impact factor: 91.245

4.  Audit of control of heparin treatment.

Authors:  A G Fennerty; P Thomas; G Backhouse; P Bentley; I A Campbell; P A Routledge
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-05

5.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

Authors:  T E Warkentin; M N Levine; J Hirsh; P Horsewood; R S Roberts; M Gent; J G Kelton
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

6.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

7.  Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.

Authors:  P Lindmarker; M Holmström; S Granqvist; H Johnsson; D Lockner
Journal:  Thromb Haemost       Date:  1994-08       Impact factor: 5.249

8.  Optimal therapeutic level of heparin therapy in patients with venous thrombosis.

Authors:  R D Hull; G E Raskob; D Rosenbloom; J Lemaire; G F Pineo; B Baylis; J S Ginsberg; A A Panju; P Brill-Edwards; R Brant
Journal:  Arch Intern Med       Date:  1992-08

9.  Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis.

Authors:  J Harenberg; K Huck; H Bratsch; G Stehle; C E Dempfle; K Mall; M Blauth; K H Usadel; D L Heene
Journal:  Haemostasis       Date:  1990

10.  Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma.

Authors:  D M Tollefsen; D W Majerus; M K Blank
Journal:  J Biol Chem       Date:  1982-03-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.